Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

52,425 results for “Shanghai Fosun Pharmaceutical (Group) Co., Ltd.”

Fosun Pharma's Innovative Drug Receives Registration Acceptance in China

Accro Bioscience Secures China Regulatory Clearance for Vitiligo Trial

Accro Bioscience Announces NMPA Clearance for Phase II/III Trial of AC-201, a Selective TYK2/JAK1 Inhibitor for Non-Segmental Vitiligo

Teva and Fosun Pharma Form Strategic Partnership for Novel Anti-PD1-IL2 Cancer Immunotherapy TEV-56278

Arcera Life Sciences and Fosun Pharma Form Strategic Partnership to Bridge Chinese Innovation with Global Markets

Dizal Submits NDA to FDA for Sunvozertinib in EGFR Exon20ins NSCLC

Fosun Pharma and MingMed Achieve Key Regulatory Milestones for Novel Therapies

Eisai Advances LEQEMBI Subcutaneous and IV Maintenance Dosing Applications for Alzheimer's Disease

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang in Greater China Deal Worth Up to RMB 215 Million Upfront

AIM Vaccine Submits 13-Valent Pneumonia Conjugate Vaccine for Approval After Positive Phase III Results

Page 1 of 1985